Literature DB >> 16409967

[Effects of tetramethylpyrazine on fibrosis of atrial tissue and atrial fibrillation in a canine model of congestive heart failure induced by ventricular tachypacing].

Ya-Zhou Lin1, Chun-Xuan Xu, Yu-Lian Deng, Lin Chen, Hai Huang, Jian Du.   

Abstract

OBJECTIVE: To explore the effects of tetramethylpyrazine (TMP) on fibrosis of atrial tissue and atrial fibrillation in a canine model of congestive heart failure (CHF) induced by ventricular tachypacing.
METHODS: Twenty-one healthy mongrel dogs were randomly divided into three groups, which were normal control group, untreated group and TMP-treated group. Atrial fibrillation (AF) was induced by burst of atrial pacing, after the canine model of CHF was established. The atrial tissues were sampled and stained with Mallory's trichromic stains, then the fibrosis in the atrial tissues was analyzed. The left ventricular ejection fraction (LVEF) was evaluated by echocardiography. The levels of angiotensin II (AngII), aldosterone (ALD), amino-terminal peptide of type III procollagen (PIIINP)ìlaminin (LN) and hyaluronic acid (HA) in peripheral blood were examined by radioimmunoassay.
RESULTS: The LVEF was significantly decreased in the untreated group as compared with that in the normal control group (P<0.01), while the frequencies of AF and sustaining AF were significantly increased and the AF duration was obviously prolonged in the untreated group as compared with those in the normal control group (P<0.01). The fibrosis degree in the left or right atrial tissue in the untreated group was more serious than that in the normal control group (P<0.01). The AF duration was positively correlated with the fibrosis degree in the left atrial tissue (r=0.84, P=0.018). The levels of AngII, ALD, PIIINP and HA in peripheral blood were significantly higher in the untreated group than those in the normal control group (P<0.05 or P<0.01). The level of AngII was positively correlated with the level of ALD in peripheral blood (r=0.759, P=0.048). The LVEF and the frequency of sustaining AF were both significantly improved in the TMP-treated group as compared with those in the untreated group (P<0.05). The fibrosis in the left or right atrial tissue in the untreated group was more serious than that in the untreated group (P<0.01). The levels of AngII and PIIINP in peripheral blood were also markedly higher in the TMP-treated group than those in the untreated group (P=0.05, P=0.01).
CONCLUSION: Tetramethylpyrazine has the effect of reducing the fibrosis degree of atrial tissue in dogs with CHF, and this efficacy may be related to the mechanism of decreasing the frequency of AF and shortening the AF duration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409967     DOI: 10.3736/jcim20060110

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  3 in total

1.  Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension.

Authors:  Yuqin Chen; Wenju Lu; Kai Yang; Xin Duan; Mengxi Li; Xiuqing Chen; Jie Zhang; Meidan Kuang; Shiyun Liu; Xiongting Wu; Guofa Zou; Chunli Liu; Cheng Hong; Wenjun He; Jing Liao; Chi Hou; Zhe Zhang; Qiuyu Zheng; Jiyuan Chen; Nuofu Zhang; Haiyang Tang; Rebecca R Vanderpool; Ankit A Desai; Franz Rischard; Stephen M Black; Joe G N Garcia; Ayako Makino; Jason X-J Yuan; Nanshan Zhong; Jian Wang
Journal:  Br J Pharmacol       Date:  2020-04-27       Impact factor: 8.739

Review 2.  Cardiovascular Actions and Therapeutic Potential of Tetramethylpyrazine (Active Component Isolated from Rhizoma Chuanxiong): Roles and Mechanisms.

Authors:  Ming Guo; Yue Liu; Dazhuo Shi
Journal:  Biomed Res Int       Date:  2016-05-23       Impact factor: 3.411

Review 3.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.